SynthesisNutrition reviews2026
Effect of 8-Hour Time-Restricted Eating (16/8 TRE) on Glucose Metabolism and Lipid Profile in Adults: A Systematic Review and Meta-Analysis.
Synthesis in Nutrition reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circadian Misalignment and Chrononutrition in Type 2 Diabetes: Mechanistic Insights and Translational Gaps.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextA dietary regimen that includes a fasting period of 16 hours coupled with a daily time-restricted eating (TRE) period of 8 hours (16/8 TRE) is gaining popularity; however, its effect on glycolipid metabolic markers remains unclear.
objectiveIn this systematic review and meta-analysis of reported studies we aimed to examine the effects on glycolipid metabolism of the 16/8 TRE dietary regimen compared with a control diet in adult study participants. DATA SOURCES: We searched the PubMed, MEDLINE, Cochrane Library, Scopus, and Web of Science databases for relevant articles published from database inception until January 15, 2025. DATA EXTRACTION: We extracted publication details, including data on study participant characteristics, intervention durations, and outcomes. DATA ANALYSIS: All analyses were conducted using a random-effects model with the standardized mean difference (SMD). Subgroup analyses were performed for physical activity (PA) level, participant sex, and intervention duration.
resultsIn total, 23 randomized controlled trials (RCTs)with a total of 1280 participants were included in this analysis. The 16/8 TRE intervention resulted in a slight reduction in levels of fasting glucose (SMD, -0.25; 95% CI, -0.42 to -0.08; P = .004), homeostasis model assessment for insulin resistance (HOMA-IR) (SMD, -0.16; 95% CI, -0.29 to -0.02; P = .03), and insulin levels (SMD, -0.22; 95% CI, -0.43 to -0.01; P = .04). Regarding lipid profiles, 16/8 TRE had a modest effect on high-density lipoprotein cholesterol (HDL-C) (SMD, 0.15; 95% CI: 0.01-0.29; P = .04). No significant effects were found for other markers compared to the control diet. Subgroup analysis suggested the presence of sex differences in triglycerides (TGs) and low-density lipoprotein cholesterol (LDL-C), with significant improvements in TGs (SMD, -0.52; 95% CI, -1.04 to -0.01; P = .05), and LDL-C (SMD, -0.41; 95% CI, -0.75 to -0.07; P = .02) found in studies with only male participants. Additionally, participants with higher PA levels demonstrated greater improvements in LDL-C (SMD, -0.43; 95% CI, -0.74 to -0.12; P = .007). Studies with durations exceeding 6 months showed a significant improvement in HbA1c (SMD, -0.31; 95% CI, -0.56 to -0.05; P = .02).
conclusionStudy participants who followed the 16/8 TRE showed an overall improvement in fasting glucose, HOMA-IR, insulin, and HDL-C levels compared to participants who followed the control diet. However, the effects of the 16/8 TRE in individuals were likely to have been moderated by participant sex, PA level, and intervention duration. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration No. CRD42025645789.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.